Inotiv Leverages LifeNet Health Proprietary Platform to Advance New Approach Methodologies in Translational Drug Discovery

Core Insights - Inotiv, Inc. announced a strategic initiative to integrate LifeNet Health's proprietary TruVivo system into its Discovery and Translational Sciences business, enhancing its drug development capabilities [1][3] Group 1: Company Overview - Inotiv, Inc. is a leading contract research organization focused on nonclinical and analytical drug discovery and development services, aiming to improve efficiency and reduce costs in bringing new drugs and medical devices to market [4] - The company is dedicated to supporting research and development objectives while promoting a healthier and safer world [4] Group 2: Technology and Collaboration - LifeNet Health has developed the TruVivo system, which utilizes primary human hepatocytes with human-derived feeder cells to create in vitro models that better predict human responses to therapies, addressing significant challenges in drug development [2] - The integration of the TruVivo platform into Inotiv's offerings will enhance the alignment of preclinical models with human biology and expand human-relevant tissue models beyond the liver, facilitating innovation across various human diseases [3] Group 3: Mission and Vision - Both Inotiv and LifeNet Health share a mission to accelerate scientific innovation that translates into meaningful human impact, emphasizing the importance of human-relevant technologies in preclinical research [3][5]